CD4-positive T-helper cell responses to the PASD1 protein in patients with diffuse large B-cell lymphoma

Tisagenlecleucel is indicated for pediatric and young adult patients with relapsed/refractory (r/r) B-cell acute lymphoblastic leukemia (B-ALL) and adult patients with r/r diffuse large B-cell lymphoma (DLBCL). The tisagenlecleucel chimeric antigen receptor (CAR) contains a murine single-chain variable fragment domain; hence, we examined the effects of humoral and cellular immune responses to tisagenlecleucel on clinical outcomes using 2 validated assays. Data were pooled from ELIANA (NCT02435849) and ENSIGN (NCT02228096) trials in r/r B-ALL (N=143) and the JULIET trial (NCT02445248) in r/r DLBCL (N=115). Humoral responses were determined by flow cytometric measurement of anti-murine CAR19 (mCAR19) antibodies in serum. Cellular responses were determined using T-cell production of interferon gamma in response to 2 different pools of mCAR19 peptides. Pretreatment anti-mCAR19 antibodies were detected in 81% of patients with r/r B-ALL and 94% of patients with r/r DLBCL. Posttreatment anti-mCAR19 antibodies were higher than patient-specific baseline in 42% of r/r B-ALL and 9% of r/r DLBCL patients. Pretreatment and posttreatment anti-mCAR19 antibodies did not affect tisagenlecleucel cellular kinetics including Cmax and persistence (r2<0.05), clinical response (day 28 response, duration of response, event-free survival), or safety. T-cell responses were consistent over time, with net responses <1% at baseline and posttreatment time points in the majority of patients with no effect on transgene expansion and persistence or outcomes. Presence of baseline and/or posttreatment anti-mCAR19 antibodies or T-cell responses did not alter the activity of tisagenlecleucel in patients with r/r B-ALL or r/r DLBCL.

Download Full-text

Transformation of follicular lymphoma to diffuse large B-cell lymphoma proceeds by distinct oncogenic mechanisms

Yearbook of Pathology and Laboratory Medicine ◽

10.1016/s1077-9108(08)70699-6 ◽

2008 ◽

Vol 2008 ◽

pp. 270-271

Author(s):

M. Djokic

Keyword(s):

Follicular Lymphoma ◽

B Cell ◽

Cell Lymphoma ◽

B Cell Lymphoma ◽

Large B Cell Lymphoma ◽

Large B Cell

Download Full-text

Abstract #804110: Recognizing A Rare Disease: Primary Thyroid Diffuse Large B Cell Lymphoma

Endocrine Practice ◽

10.1016/s1530-891x(20)39564-1 ◽

2020 ◽

Vol 26 ◽

pp. 264-265

Author(s):

Jessica Kunadia

Keyword(s):

B Cell ◽

Rare Disease ◽

Cell Lymphoma ◽

B Cell Lymphoma ◽

Large B Cell Lymphoma ◽

Large B Cell

Download Full-text

Abstract #844: Pituitary Mass with Anterior Hypopituitarism from Metastatic Diffuse Large B Cell Lymphoma

Endocrine Practice ◽

10.1016/s1530-891x(20)44589-6 ◽

2017 ◽

Vol 23 ◽

pp. 185-186

Author(s):

Christine Lee ◽

Kjersti Kirkeby

Keyword(s):

B Cell ◽

Cell Lymphoma ◽

B Cell Lymphoma ◽

Pituitary Mass ◽

Large B Cell Lymphoma ◽

Large B Cell

Download Full-text

Lymphome

Praxis ◽

10.1024/1661-8157/a002237 ◽

2016 ◽

Vol 105 (1) ◽

pp. 47-52 ◽

Cited By ~ 1

Author(s):

Andreas Lohri

Keyword(s):

B Cell ◽

Cell Lymphoma ◽

B Cell Lymphoma ◽

Staging System ◽

Maligne Lymphome ◽

Interim Pet ◽

Large B Cell Lymphoma ◽

Ann Arbor ◽

Large B Cell

Zusammenfassung. Maligne Lymphome unterteilen sich zwar in über 60 Entitäten, das grosszellige B-Zell-Lymphom, das follikuläre Lymphom, der Hodgkin und das Mantelzell-Lymphom machen aber mehr als die Hälfte aller Lymphome aus. Im revidierten Ann Arbor staging system gelten die Suffixe «A» und «B» nur noch für den Hodgkin. «E» erscheint nur noch bei Stadien I und II. Eine Knochenmarksuntersuchung wird beim Hodgkin nicht mehr verlangt, beim DLBCL (Diffuse large B cell lymphoma) nur, falls das PET keinen Knochenmark-Befall zeigt. Der PET-Untersuchung, speziell dem Interim-PET, kommt eine entscheidende Bedeutung zu. PET-gesteuerte Therapien führen zu weniger Toxizität. Gezielt wirkende Medikamente mit eindrücklicher Wirksamkeit wurden neu zugelassen. Deren Kosten sind hoch. Eine strahlen- und chemotherapiefreie Behandlung maligner Lymphome wird in Zukunft möglich sein.

Download Full-text